Cargando…
Preliminary observations on soluble programmed cell death protein-1 as a prognostic and predictive biomarker in patients with metastatic melanoma treated with patient-specific autologous vaccines
Because of its role as an immune checkpoint, levels of soluble programmed cell death protein-1 (sPD-1) could be useful as a prognostic biomarker or predictive biomarker in cancer patients treated with vaccines. Very low levels of sPD-1 may indicate lack of an existing anti-cancer immune response; ve...
Autores principales: | Dillman, Robert O., Nistor, Gabriel I., McLelland, Bryce T., Hsieh, Candace, Poole, Aleksandra J., Cornforth, Andrew N., Keirstead, Hans S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731107/ https://www.ncbi.nlm.nih.gov/pubmed/31523394 http://dx.doi.org/10.18632/oncotarget.27164 |
Ejemplares similares
-
Phase III randomized, double-blinded, placebo-controlled multicenter trial of melapuldencil-t: autologous dendritic cells loaded with irradiated autologous tumor cells (dc-tc) in gm-csf in patients with metastatic melanoma
por: Dillman, Robert, et al.
Publicado: (2014) -
Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
por: Dillman, Robert O., et al.
Publicado: (2023) -
Functional properties of patient-derived melanoma cancer stem cells
por: Nistor, Gabriel, et al.
Publicado: (2015) -
Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma
por: Dillman, Robert O, et al.
Publicado: (2019) -
Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses
por: Dillman, Robert O., et al.
Publicado: (2018)